2seventy bio ( (TSVT) ) has issued an announcement.
2seventy bio, Inc. has announced the termination of enrollment in the Phase 3 KarMMa-9 study of Abecma® for multiple myeloma due to an improved treatment landscape and fewer eligible patients. The decision is expected to save over $80 million and hasten the company’s break-even point to 2025. Despite this, Abecma’s U.S. revenues are projected to grow by approximately 30% from the previous quarter, indicating a positive outlook for the drug’s performance in the market.
Find detailed analytics on TSVT stock on TipRanks’ Stock Analysis page.